The dramatic social, personal and economic impacts of individuals suffering from Schizophrenia (SZ) have led governments to consider this disease a world public health problem. Several studies have shown that most of the consequences of this psychiatric disorder rely on a group of symptoms often hidden from the clinical evaluation at a first glance. These symptoms, so called cognitive deficits (CD), range from perception alterations, through dysexecutive syndrome, and memory dysfunctions, among others. These CD have become hallmark of SZ, as they are the only long-term indicator of personal and social dysfunctions in SZ patients. Thus, the search for new treatments against these deficits is considered the next frontier in modern research of SZ.
"Trends in clinical, molecular and social approaches of SZ" seeks to be a comprehensive reference covering one of the most promising developments in the field of SZ research. The planned layout of this research topic includes: An overview of the core features of the CD such as attention alterations, working memory dysfunctions, executive and social dysfunctions. Besides, this research topic includes a section of the new treatments in SZ such as cognitive remediation therapy, glutamatergic-based compounds new treatments, fMRI biofeedback, and others. Finally, it includes a section of CD common to SZ and other psychiatric disorders as Alzheimer disease.
The intended readership includes clinicians specialized in psychiatry, psychologists, neuroscientists and other professionals working in research organizations and corporations engaged in research and development of psychopharmaceuticals. The contributors to this research topic will be experts in the field of clinical psychiatry, molecular neurosciences and psychopharmacology, and outstanding researchers in SZ. We aim to provide a forum for experts in the field to present novel research findings, review, mini-review, and Hypothesis & theory articles.
The dramatic social, personal and economic impacts of individuals suffering from Schizophrenia (SZ) have led governments to consider this disease a world public health problem. Several studies have shown that most of the consequences of this psychiatric disorder rely on a group of symptoms often hidden from the clinical evaluation at a first glance. These symptoms, so called cognitive deficits (CD), range from perception alterations, through dysexecutive syndrome, and memory dysfunctions, among others. These CD have become hallmark of SZ, as they are the only long-term indicator of personal and social dysfunctions in SZ patients. Thus, the search for new treatments against these deficits is considered the next frontier in modern research of SZ.
"Trends in clinical, molecular and social approaches of SZ" seeks to be a comprehensive reference covering one of the most promising developments in the field of SZ research. The planned layout of this research topic includes: An overview of the core features of the CD such as attention alterations, working memory dysfunctions, executive and social dysfunctions. Besides, this research topic includes a section of the new treatments in SZ such as cognitive remediation therapy, glutamatergic-based compounds new treatments, fMRI biofeedback, and others. Finally, it includes a section of CD common to SZ and other psychiatric disorders as Alzheimer disease.
The intended readership includes clinicians specialized in psychiatry, psychologists, neuroscientists and other professionals working in research organizations and corporations engaged in research and development of psychopharmaceuticals. The contributors to this research topic will be experts in the field of clinical psychiatry, molecular neurosciences and psychopharmacology, and outstanding researchers in SZ. We aim to provide a forum for experts in the field to present novel research findings, review, mini-review, and Hypothesis & theory articles.
